<DOC>
	<DOCNO>NCT00989261</DOCNO>
	<brief_summary>AC220 administer daily oral solution give continuously 28-day treatment cycle , without rest period , disease progression , relapse , intolerance drug , elective allogeneic hematopoietic stem cell transplantation ( HSCT ) .</brief_summary>
	<brief_title>Efficacy Study AC220 Treat Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Current enrollment open FLT3ITD positive , Cohort 1 . 1 . Males females age ≥18 year second relapse refractory . 2 . Males females age ≥60 year first relapse refractory . 3 . Must baseline bone marrow sample take . 4 . Morphologically documented primary AML AML secondary myelodysplastic syndrome ( MDS ≥20 % bone marrow peripheral blast ) , define World Health Organization ( WHO ) criterion , confirm pathology review treat institution . 5 . Able swallow liquid study drug . 6 . ECOG performance status 0 2 7 . In absence rapidly progress disease , interval prior treatment time AC220 administration least 2 week cytotoxic agent least 5 halflives noncytotoxic agent . The use chemotherapeutic antileukemic agent hydroxyurea permit study possible exception intrathecal ( IT ) therapy discretion Investigator agreement Sponsor . 8 . Persistent chronic clinically significant nonhematological toxicity prior treatment must ≤Grade 1 . 9 . Prior therapy FLT3 inhibitor permit , except previous treatment AC220 . 10 . Serum creatinine ≤1.5 × ULN glomerular filtration rate ( GFR ) &gt; 30 mL/min 11 . Serum potassium , magnesium , calcium level least within institutional normal limit . 12 . Total serum bilirubin ≤1.5 × ULN 13 . Serum aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) ≤2.5 × ULN 14 . Females childbearing potential must negative pregnancy test ( urine βhCG ) . 15 . Females childbearing potential sexually mature male must agree use medically accept method contraception throughout study . 16 . Written informed consent must provide . 1 . Patients age 85 year except discretion Investigator agreement Sponsor . 2 . Diagnosis acute promyelocytic leukemia 3 . Diagnosis chronic myelogenous leukemia ( CML ) blast crisis 4 . AML relapse refractory 3 previous line chemotherapy ( and/or HSCT ) treatment 5 . AML antecedent MDS secondary prior chemotherapy 6 . Persistent clinically significant nonhematological toxicity Grade &gt; 1 NCI CTCAE v4 prior chemotherapy 7 . Patients HSCT within 100 day transplant and/or still take immunosuppressive drug and/or clinically significant graftversushost disease require treatment and/or &gt; Grade 1 persistent non hematological toxicity relate transplant 8 . Clinically active central nervous system ( CNS ) leukemia . Patients CNS leukemia , control , still receive IT therapy study entry may consider eligible continue receive IT therapy discretion Investigator agreement Sponsor . 9 . Patients previously receive AC220 10 . Disseminated intravascular coagulation ( DIC ) ( diagnosis laboratory clinical assessment ) 11 . Major surgery within 4 week prior enrollment study 12 . Radiation therapy within 4 week prior , concurrent study 13 . Use concomitant drug prolong QT/QTc interval and/or CYP3A4 inhibitor prohibit exception antibiotic , antifungal , antimicrobial use standard care prevent treat infection drug consider absolutely essential care patient . 14 . Uncontrolled significant cardiovascular disease 15 . Women pregnant , lactating , unwilling use contraception childbearing potential 16 . Men unwilling use contraception partner childbearing potential 17 . Active , uncontrolled infection 18 . Human immunodeficiency virus positivity 19 . Active hepatitis B C active liver disease 20 . History cancer , except Stage 1 cervix nonmelanotic skin cancer , possible exception patient complete remission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>AC220</keyword>
	<keyword>acute</keyword>
	<keyword>FLT3</keyword>
	<keyword>inhibitor</keyword>
	<keyword>kinase</keyword>
	<keyword>leukemia</keyword>
	<keyword>leukaemia</keyword>
	<keyword>myeloid</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>